Practice guidelines acknowledge the importance of patient preferences in determining the appropriate treatment of benign prostatic hyperplasia (BPH). Recent literature suggests that patient and physician perspectives and satisfaction with BPH treatment management may differ; this may have an impact on clinical outcomes and patient compliance. This review evaluates patients' and physicians' pref...

Benign prostatic hyperplasia (BPH; Pic. 1) is characterized by increased size of the prostate leading to difficulties with passing the urine. The cells of prostate may increase in numbers (hyperplasia) or in size (hypertrophy) resulting in larger size of prostate. As result, prostatic nodules form in the transition zone of the prostate, which is the area where the prostate is surrounding the ur...

Benign prostatic hyperplasia (BPH) is characterized by an enlargement of the prostate, causing lower urinary tract symptoms in elderly men worldwide. However, the molecular mechanism underlying the pathogenesis of BPH is unclear. Anoctamin1 (ANO1) encodes a Ca(2+)-activated chloride channel (CaCC) that mediates various physiological functions. Here, we demonstrate that it is essential for testo...

This was a double-blinded placebo-controlled clinical trial, which including 98 patients clinically diagnosed as various degrees of benign prostatic hyperplasia and confirmed by pelvic ultrasonography along with uroflowmetry investigations. Himplasia was administered as 1 tablet, twice daily for 6 months. All the patients were clinically examined every month for 6 months and we repeat ultrasono...

Benign prostatic hyperplasia (BPH) is most common in men 40 years and above. It rarely occurs childhood. As a result of the scarcity cases, pathogenesis not clear, treatment BPH this age group challenging. This report focuses on 13-year-old patient diagnosed with histologically confirmed BPH, having presented 2-year history recurrent hematuria acute urinary retention. Magnetic resonance imaging...

Prostatic Adenocarcinoma (PA) and Benign Prostatic Hyperplasia (BPH) have their etiology not fully understood mainly in glycidic aspects. Glycan changes are associated with cell alterations where glycosylation is carried out by glycosyltransferases, such as fucosyltransferases (FUTs). These enzymes catalyze the insertion of L-fucose residues in a variety of glycan structures often in the final ...

Prostate-specific antigen (PSA) is the one of the most valuable tumor markers for the early detection and management of prostate carcinoma, but not an ideal one because of poor specificity in the case of prostatic hypertrophy and other benign conditions. In order to overcome this drawback some other parameters as is free to total ratio (F/T) PSA and PSA density (PSAD) are introduced. It has bee...

Aims: Benign prostatic hyperplasia and adenocarcinoma are common diseases that account for considerable morbidity and mortality of ageing population. In cancer related deaths in men, the prostatic cancer is the second most common to lung cancer. Purpose of this study is to analyze various clinicopathological features in benign and malignant prostatic lesions, to correlate of benign and malignan...

Proteomic analysis of formalin-fixed paraffin-embedded (FFPE) tissue would enable retrospective biomarker investigations of this vast archive of pathologically characterized clinical samples that exist worldwide. These FFPE tissues are, however, refractory to proteomic investigations utilizing many state of the art methodologies largely due to the high level of covalently cross-linked proteins ...

Clinical BPH as a disease has been defined as benign prostatic enlargement (BPE) [1,2]; however in clinical practice we still see many patients with no enlargement, with prostate volume less than 20 g still causing symptoms and obstruction [3]. How can this be explained? To solve the puzzle, we first need to redefine clinical BPH. We need to go back to the basic fundamental pathology of BPH, wh...